← All drugs Report issue

cd123 cll-1 dual-target car-t cells

Cell therapyexperimental

Clinical trial activity

0 trials · 0 clinical orgs · 0 marketing orgs

Phase 1

0

Phase 2

0

Phase 3

0

Phase 4

0

Mechanism of action

C-type lectin domain family 12 member AImmunity, passive
CLEC12A immunity, passive
- C-type lectin domain family 12 member A (CLEC12A) ↗
Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
- Interleukin-3 receptor subunit alpha (IL3RA) ↗

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No